RYO UKAI

Dr. RYO UKAI


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in Journal of Neurotrauma
Verified
Journal Article
Closed access
RURYO UKAI
RYO UKAI
OHOsamu Honmou
Osamu Honmou
KHKuniaki Harada
Kuniaki Harada
KHKiyohiro Houkin
Kiyohiro Houkin
HHHirofumi Hamada
Hirofumi Hamada
JKJeffery D. Kocsis
Jeffery D. Kocsis
Intravenous delivery of mesenchymal stem cells (MSCs) prepared from bone marrow (BMSCs) reduces infarction volume and ameliorates functional deficits in a rat cerebral ischemia model. MSC-like multipotent precursor cells (PMSCs) have also been suggested to exist in peripheral blood. To test the hypothesis that treatment with PMSCs may have a therapeutic benefit in stroke, we compared the efficacy of systemic delivery of BMSCs and PMSCs. A permanent middle cerebral artery occlusion (MCAO) in rat was induced by intraluminal vascular occlusion with a microfilament. Rat BMSCs and PMSCs were prepared in culture and intravenously injected into the rats 6 h after MCAO. Lesion size was assessed at 6 h, and 1, 3, and 7 days using MR imaging and histology. The hemodynamic change of cerebral blood perfusion on stroke was assessed the same times using perfusion-weighted image (PWI). Functional outcome was assessed using the treadmill stress test. Both BMSCs and PMSCs treated groups had reduced lesion volume, improved regional cerebral blood flow, and functional improvement compared to the control group. The therapeutic benefits of both MSC-treated groups were similar. These data suggest that PMSCs derived from peripheral blood could be an important cell source of cell therapy for stroke.

1 September 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
RURYO UKAI
RYO UKAI
TMTakeshi Mikami
Takeshi Mikami
HNHiroshi Nagahama
Hiroshi Nagahama
MWMasahiko Wanibuchi
Masahiko Wanibuchi
YAYukinori Akiyama
Yukinori Akiyama
NMNobuhiro Mikuni
Nobuhiro Mikuni

13 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MMMari Maeda-Yamamoto
Mari Maeda-Yamamoto
OHOsamu Honmou
Osamu Honmou
MSMasanori Sasaki
Masanori Sasaki
AHAkane Haseda
Akane Haseda
KHKagami-Katsuyama Hiroyo
Kagami-Katsuyama Hiroyo
JNJun Nishihira
Jun Nishihira
The purple-flesh potato (Solanum tuberosum L.) cultivar “Shadow Queen” (SQ) naturally contains anthocyanins. This randomized, double-blind, placebo-controlled study determines whether ingesting purple potatoes increases the number of mesenchymal stem cells (MSC) and improves stress response, a minor health complaint in healthy adults (registration number: UMIN000038876). A total of 15 healthy subjects (ages: 50–70 years) with minor health complaints were randomly assigned to one of two groups. For 8 weeks, the placebo group received placebo potatoes cv. “Haruka” and the test group received test potato cv. SQ containing 45 mg anthocyanin. The MSC count and several stress responses were analyzed at weeks 0 and 8 of the intake periods. The ingestion of a SQ potato did not affect the MSC count but markedly improved psychological stress response, irritability, and depression as minor health complaints compared with “Haruka”. No adverse effects were noted. Hence, an 8-week intake of SQ could improve stress responses.

31 January 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
NYNaomi Yasuda
Naomi Yasuda
YKYosuke Kuroda
Yosuke Kuroda
TIToshiro Ito
Toshiro Ito
MSMasanori Sasaki
Masanori Sasaki
SOShinichi Oka
Shinichi Oka
NKNobuyoshi Kawaharada
Nobuyoshi Kawaharada
OBJECTIVES: Ischaemic spinal cord injury (SCI) is one of the most serious complications of aortic surgery. Ischaemic SCIs occur due to various aetiologies, and prediction of the risk is difficult. Magnetic resonance imaging (MRI) is useful to detect the details of spinal cord infarction. There are few studies about MRI for evaluating ischaemic SCI after cardiovascular surgery and aortic events. We report 9 cases of postoperative ischaemic SCI and analyse their MRI features.METHODS: T2-weighted MRI scans of 9 patients who developed ischaemic SCI due to cardiovascular surgery and aortic events between 2012 and 2017 were evaluated.RESULTS: In all patients, high-intensity areas were observed on T2-weighted magnetic resonance images. The site of infarction was the thoracic spinal cord level (9 cases) and additionally at the lumbar spinal cord level (5 cases). The area of infarction area was categorized based on the arterial territory: anterior spinal artery territory (3 cases), posterior spinal artery territory (2 cases), spinal sulcal artery territory (1 case) and artery of Adamkiewicz territory (3 cases).CONCLUSIONS: MRI revealed the infarction sites in all cases and the differences in the infarction patterns in each case. MRI could thus be useful for investigating the aetiology of ischaemic SCI following aortic surgeries and events.

6 July 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
SOShinichi Oka
Shinichi Oka
TYTomohiro Yamaki
Tomohiro Yamaki
MSMasanori Sasaki
Masanori Sasaki
RURYO UKAI
RYO UKAI
MTMitsuhiro Takemura
Mitsuhiro Takemura
OHOsamu Honmou
Osamu Honmou
Background: Brain injuries resulting from motor vehicle accidents and falls, as well as hypoxic insults and other conditions, are one of the leading causes of disability and death in the world. Current treatments are limited but include continuous rehabilitation, especially for chronic brain injury. Recent studies have demonstrated that the intravenous infusion of mesenchymal stem cells (MSCs) has therapeutic efficacy for several neurological diseases, including stroke and spinal cord injury. Objective: The objective of our investigator-initiated clinical trial is to assess the safety and potential efficacy of the intravenous infusion of autoserum-expanded autologous MSCs for patients with chronic brain injury. Methods: The (phase 2) trial will be a single-arm, open-label trial with the primary objective of confirming the safety and efficacy of autoserum-expanded autologous MSCs (STR-01; produced under good manufacturing practices) when administered to patients with chronic brain injury. The estimated number of enrolled participants is 6 to 20 patients with a modified Rankin Scale grade of 3 to 5. The assessment of safety and the proportion of cases in which the modified Rankin Scale grade improves by 1 point or more at 180 days after the injection of STR-01 will be performed after MSC infusion. Results: We received approval for our clinical trial from the Japanese Pharmaceuticals and Medical Devices Agency on December 12, 2017. The trial will be completed on June 11, 2023. The registration term is 5 years. The recruitment of the patients for this trial started on April 20, 2018, at Sapporo Medical University Hospital in Japan. Conclusions: Our phase 2 study will aim to address the safety and efficacy of the intravenous infusion of MSCs for patients with chronic brain injury. The use of STR-01 has been performed for patients with cerebral infarction and spinal cord injury, providing encouraging results. The potential therapeutic efficacy of the systemic administration of autoserum-expanded autologous MSCs for chronic brain injury should be evaluated, given its safety and promising results for stroke and spinal cord injury. Trial Registration: Japan Medical Association Center for Clinical Trials JMA-IIA00333; https://tinyurl.com/nzkdfnbc International Registered Report Identifier (IRRID): DERR1-10.2196/37898

20 November 2023 in Interdisciplinary Neurosurgery
Verified
Journal Article
Open access
TYTomohiro Yamaki
Tomohiro Yamaki
SOShinichi Oka
Shinichi Oka
SISatoshi Iyama
Satoshi Iyama
MSMasanori Sasaki
Masanori Sasaki
RORie Onodera
Rie Onodera
OHOsamu Honmou
Osamu Honmou